SABCS 2016

Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.

Findings from a preclinical study of PI3K inhibitor taselisib’s mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.

Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).

An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Cancer drug prices will probably continue their steady climb.

Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.

A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.